TXMD
Income statement / Annual
Last year (2024), TherapeuticsMD, Inc.'s total revenue was $1.76 M,
an increase of 35.25% from the previous year.
In 2024, TherapeuticsMD, Inc.'s net income was -$2.18 M.
See TherapeuticsMD, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.76 M |
$1.30 M |
$69.96 M |
$2.57 M |
$64.87 M |
$49.65 M |
$16.10 M |
$16.78 M |
$19.36 M |
$20.14 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$1.40 M
|
$1.40 M
|
$15.98 M
|
$6.34 M
|
$2.74 M
|
$2.64 M
|
$4.19 M
|
$4.51 M
|
| Gross Profit |
$1.76 M
|
$1.30 M
|
$68.57 M
|
$1.17 M
|
$48.90 M
|
$43.31 M
|
$13.36 M
|
$14.14 M
|
$15.17 M
|
$15.64 M
|
| Gross Profit Ratio |
1
|
1
|
0.98
|
0.46
|
0.75
|
0.87
|
0.83
|
0.84
|
0.78
|
0.78
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.43 M
|
$19.79 M
|
$27.30 M
|
$33.85 M
|
$53.94 M
|
$72.04 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$57.90 M
|
$72.75 M
|
$76.95 M
|
$60.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$1.19 M
|
$0.00
|
$117.05 M
|
$114.23 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$0.00
|
$56.71 M
|
$72.75 M
|
$194.01 M
|
$174.73 M
|
$115.99 M
|
$57.70 M
|
$51.35 M
|
$28.72 M
|
| Other Expenses |
$6.52 M
|
$9.83 M
|
$10.67 M
|
$8.00 M
|
$0.00
|
$0.00
|
$0.00
|
$695.63 K
|
$367.32 K
|
$95.72 K
|
| Operating Expenses |
$6.52 M
|
$9.83 M
|
$67.38 M
|
$80.75 M
|
$204.44 M
|
$194.52 M
|
$143.58 M
|
$91.77 M
|
$105.42 M
|
$100.83 M
|
| Cost And Expenses |
$6.52 M
|
$9.83 M
|
$68.77 M
|
$82.15 M
|
$220.41 M
|
$200.85 M
|
$146.32 M
|
$94.41 M
|
$109.61 M
|
$105.33 M
|
| Interest Income |
$144.90 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.70 K
|
$10.82 K
|
$17.44 K
|
| Interest Expense |
$9.50 K
|
$0.00
|
$0.00
|
$32.92 M
|
$28.58 M
|
$17.38 M
|
$4.68 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$509.00 K
|
$438.50 K
|
$1.20 M
|
$736.00 K
|
$4.07 M
|
$1.39 M
|
$293.89 K
|
$213.12 K
|
$132.45 K
|
$62.40 K
|
| EBITDA |
-$2.98 M |
-$8.08 M |
$11.86 M |
-$70.84 M |
-$153.41 M |
-$158.23 M |
-$127.65 M |
-$76.71 M |
-$89.74 M |
-$85.13 M |
| EBITDA Ratio |
-1.69
|
-6.21
|
0.17
|
-27.53
|
-2.36
|
-3.19
|
-7.93
|
-4.57
|
-4.64
|
-4.23
|
| Operating Income Ratio |
-2.7
|
-6.55
|
0.02
|
-30.93
|
-2.4
|
-3.05
|
-8.09
|
-4.63
|
-4.66
|
-4.23
|
| Total Other Income/Expenses Net |
$2.42 M
|
$781.00 K
|
-$117.00 K
|
$272.00 K
|
-$27.98 M
|
-$24.94 M
|
-$2.40 M
|
$703.33 K
|
$378.14 K
|
$113.16 K
|
| Income Before Tax |
-$2.34 M
|
-$7.74 M
|
$1.07 M
|
-$79.31 M
|
-$183.52 M
|
-$176.15 M
|
-$132.62 M
|
-$76.93 M
|
-$89.88 M
|
-$85.08 M
|
| Income Before Tax Ratio |
-1.33
|
-5.95
|
0.02
|
-30.82
|
-2.83
|
-3.55
|
-8.24
|
-4.58
|
-4.64
|
-4.22
|
| Income Tax Expense |
-$31.00 K
|
-$43.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$7.70 K
|
$367.32 K
|
-$17.44 K
|
| Net Income |
-$2.18 M
|
-$10.28 M
|
$112.00 M
|
-$172.42 M
|
-$183.52 M
|
-$176.15 M
|
-$132.62 M
|
-$76.93 M
|
-$89.88 M
|
-$85.08 M
|
| Net Income Ratio |
-1.24
|
-7.89
|
1.6
|
-67.01
|
-2.83
|
-3.55
|
-8.24
|
-4.58
|
-4.64
|
-4.22
|
| EPS |
-0.19 |
-0.55 |
-10.35 |
-25.83 |
-38.58 |
-39.79 |
-29.47 |
-18.71 |
-22.92 |
-24.56 |
| EPS Diluted |
-0.19 |
-0.74 |
-10.35 |
-25.83 |
-38.58 |
-39.79 |
-29.47 |
-18.71 |
-22.92 |
-24.56 |
| Weighted Average Shares Out |
$11.53 M
|
$10.44 M
|
$9.03 M
|
$7.96 M
|
$5.51 M
|
$4.93 M
|
$4.50 M
|
$4.11 M
|
$3.92 M
|
$3.46 M
|
| Weighted Average Shares Out Diluted |
$11.53 M
|
$10.44 M
|
$9.03 M
|
$7.96 M
|
$5.51 M
|
$4.93 M
|
$4.50 M
|
$4.11 M
|
$3.92 M
|
$3.46 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
